ArticleDie Naturwissenschaften2025
Epidemiology of acute myeloid leukemia in children and adolescents (1990-2021): a global burden of disease study.
Article in Die Naturwissenschaften, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Health-Related Quality of Life in Children with Acute Leukaemia and Central Nervous System Tumours: Current Evidence and Future Directions.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) remains a significant global health concern in children, though its epidemiological landscape has markedly changed over recent decades. Understanding these evolving trends can guide targeted healthcare strategies and resource allocation. Utilizing data from the Global Burden of Disease (GBD) database spanning 1990-2021, we analyzed global, regional, and national trends in AML incidence, mortality, and disability-adjusted life years (DALYs) among children and adolescents. We applied annual percentage change (APC), estimated annual percentage change (EAPC), and correlations with the socio-demographic index (SDI) to quantify trends and influencing factors. From 1990 to 2021, global childhood AML incidence decreased by 37%, with mortality and DALYs declining by 40% and 42%, respectively. The most pronounced reductions occurred in children under 5 years of age. Substantial disparities emerged across SDI regions, with the high-middle SDI group exhibiting the sharpest declines in incidence (EAPC = - 2.96%), mortality (-3.44%), and DALYs (-3.51%). In contrast, the low SDI region saw mortality rise by 8% and DALYs increase by 5%. South Asia carried the highest absolute disease burden, while Oceania recorded the highest population-adjusted rates. Nationally, China reported the greatest incidence and India the highest mortality, despite both countries achieving significant reductions. Despite aggregate gains, childhood AML burden remains concentrated in lower-SDI settings, where exposure-related attribution is rising and outcome improvements lag. Prioritizing prevention, earlier diagnosis, and equitable access to definitive care is essential to narrow these disparities and accelerate global progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.